<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02786875</url>
  </required_header>
  <id_info>
    <org_study_id>DEDiCa</org_study_id>
    <secondary_id>2015-005147-14</secondary_id>
    <nct_id>NCT02786875</nct_id>
  </id_info>
  <brief_title>Diet, Exercise and Vitamin D in Breast Cancer Recurrence</brief_title>
  <acronym>DEDiCa</acronym>
  <official_title>The Effect of the Combination of Low Glycemic Index Diet, Exercise and Vitamin D on Breast Cancer Recurrence: DEDiCa Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Catania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to reduce breast cancer recurrence and hence increase
      disease-free survival through a lifestyle program that includes a low glycemic diet, physical
      activity and vitamin D supplementation in women with breast cancer living in a Mediterranean
      country.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to reduce breast cancer recurrence and hence increase disease-free
      survival through either a high intensity or a lower intensity lifestyle program that includes
      low glycemic index diet, physical activity and supplementation with vitamin D, for 33 months,
      in women living in Italy who have been surgically treated for breast cancer (either late
      stage or early stage but highly proliferative) within the previous 12 months. The objectives
      of the study are: to determine if the high intensity program is more efficacious than the
      lower intensity program in: 1) reducing breast cancer recurrence and 2) improving glycemic,
      hormonal, cardiovascular and cancer-related epigenetic markers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS) calculated as the percentage of patients alive without recurrence of disease at study end (up to 33 months from randomization).</measure>
    <time_frame>33 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in glycemic markers</measure>
    <time_frame>up to 33 months</time_frame>
    <description>blood levels of glucose, glycated hemoglobin, insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hormonal markers</measure>
    <time_frame>upt to 33 months</time_frame>
    <description>insulin-like growth factor-1 (IGF-1), estradiol, testosterone, sex hormone binding globulin (SHBG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cardiovascular risk factors</measure>
    <time_frame>up to 33 months</time_frame>
    <description>body weight, waist circumference, blood pressure, cholesterol, triglycerides, C-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in epigenetic factors</measure>
    <time_frame>up to 33 months</time_frame>
    <description>microRNA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">506</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group A (high intensity program):</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (lower intensity program)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>low Glycemic Index Mediterranean diet</intervention_name>
    <description>All carbohydrate foods will be low GI choices (GI&lt;70 on bread scale, e.g. legumes, pasta al dente, barley, oat, apples, oranges, berries, nuts) within a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, &lt;7% SFA).</description>
    <arm_group_label>Group A (high intensity program):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mediterranean diet</intervention_name>
    <description>General recommendations for a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, &lt;7% SFA).</description>
    <arm_group_label>Group B (lower intensity program)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Moderate physical activity</intervention_name>
    <description>Brisk walk of at least 30min per day (or approximately 5000 steps) more than the habitual physical activity.</description>
    <arm_group_label>Group A (high intensity program):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Basic physical activity</intervention_name>
    <description>General recommendations for physical activity</description>
    <arm_group_label>Group B (lower intensity program)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>high level Vitamin D</intervention_name>
    <description>Vitamin D supplement (cholecalciferol) up to 4000 IU/day to reach normal blood levels of 60-80 ng/ml of 25(OH)D.</description>
    <arm_group_label>Group A (high intensity program):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>normal level Vitamin D</intervention_name>
    <description>Vitamin D (cholecalciferol) will be given only if vitamin D insufficiency is detected to bring blood levels up to normal ranges of 30ng/mL.</description>
    <arm_group_label>Group B (lower intensity program)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women with primary diagnosis of histologically confirmed breast cancer (T1 with
             Ki67≥30%, T2, T3 without metastasis) within 12 months from diagnosis.

          2. Age ≥ 30 and &lt; 75 years.

          3. Patients who are able to comprehend and are willing to sign the consent form and are
             able to adhere to the protocol including scheduled clinic visits and assigned
             treatment.

        Exclusion Criteria:

          1. Patients who do not possess the inclusion criteria for this study.

          2. Patients with sarcoidosis or other granulomatous diseases or with hypercalcemia
             (Ca&gt;11mg/dL).

          3. Patients with any previous or current concomitant other malignant cancer.

          4. Pregnant or lactating women.

          5. Patients with AIDS diagnosis

          6. Patients with severe renal insufficiency

          7. Patients with kidney stones (nephrocalcinosis or nephrolithiasis)

          8. Patients participating in other lifestyle clinical trials
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Montella, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute Naples (Italy)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Livia S Augustin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital (Toronto, Canada) and National Cancer Institute Naples (Italy)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Libra, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Catania, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Livia S Augustin, PhD</last_name>
    <phone>+39 081 5903395</phone>
    <email>livia.augustin@utoronto.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Grimaldi, DSc</last_name>
    <phone>+39 081 5903395</phone>
    <email>m.grimaldi@istitutotumori.na.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Cannizzaro</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Mediterranea</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Vincenzo</name>
      <address>
        <city>Taormina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <last_update_submitted>October 6, 2017</last_update_submitted>
  <last_update_submitted_qc>October 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lifestyle</keyword>
  <keyword>low glycemic index diet</keyword>
  <keyword>exercise</keyword>
  <keyword>vitamin D</keyword>
  <keyword>breast cancer</keyword>
  <keyword>Mediterranean diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

